{"id":"NCT01369355","sponsor":"Janssen Research & Development, LLC","briefTitle":"A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)","officialTitle":"A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Subjects With Moderately to Severely Active Crohn's Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-09-13","primaryCompletion":"2015-06-10","completion":"2019-10-01","firstPosted":"2011-06-08","resultsPosted":"2017-02-23","lastUpdate":"2025-02-04"},"enrollment":1282,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Crohn's Disease","Colitis","IBD","Inflammatory Bowel Disease"],"interventions":[{"type":"DRUG","name":"Placebo SC","otherNames":[]},{"type":"DRUG","name":"Placebo IV","otherNames":[]},{"type":"DRUG","name":"Ustekinumab 90 mg SC q8w","otherNames":[]},{"type":"DRUG","name":"Ustekinumab 130 mg IV","otherNames":[]},{"type":"DRUG","name":"Ustekinumab 90 mg SC q12w","otherNames":[]}],"arms":[{"label":"001","type":"PLACEBO_COMPARATOR"},{"label":"002","type":"EXPERIMENTAL"},{"label":"003","type":"EXPERIMENTAL"},{"label":"004","type":"EXPERIMENTAL"},{"label":"005","type":"EXPERIMENTAL"},{"label":"006","type":"PLACEBO_COMPARATOR"}],"summary":"The primary purpose of this study is to evaluate the efficacy and safety of 2 maintenance regimens of ustekinumab administered subcutaneously to patients with moderately to severely active Crohn's disease who responded to treatment with intravenous ustekinumab in studies CNTO1275CRD3001 and CNTO1275CRD3002, compared to subcutaneously administered placebo.","primaryOutcome":{"measure":"Number of Participants With Clinical Remission at Week 44","timeFrame":"Week 44","effectByArm":[{"arm":"Placebo Subcutaneously (SC)","deltaMin":47,"sd":null},{"arm":"Ustekinumab 90 Milligram (mg) SC Every 12 Weeks (q12w)","deltaMin":63,"sd":null},{"arm":"Ustekinumab 90 mg SC q8w","deltaMin":68,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.040"},{"comp":"OG000 vs OG002","p":"0.005"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":3},"locations":{"siteCount":220,"countries":["United States","Australia","Austria","Belgium","Brazil","Bulgaria","Canada","Croatia","Czechia","Denmark","France","Germany","Hungary","Iceland","Ireland","Israel","Japan","Netherlands","New Zealand","Poland","Russia","Serbia","South Africa","South Korea","Spain","United Kingdom"]},"refs":{"pmids":["40357993","38310565","37391056","37368103","36150926","34077627","33618023","32964215","31279870","31158271","30739254","29909019","29797519","29409871","29142515","27959607"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":22,"n":133},"commonTop":["Nasopharyngitis","Crohn's Disease","Arthralgia","Abdominal Pain","Upper Respiratory Tract Infection"]}}